Novartis Receives FDA Approval for Flucelvax®, the First Cell-Culture Vaccine in US to Help Protect Against Seasonal Influenza

-Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years1-Flucelvax is the only influenza vaccine of its kind in the US and does not contain any preservatives, such as thimerosal, or antibiotics2-Approval demonstrates Novartis leadership in advancing novel influenza vaccine research and manufacturing technologies

Summary:

-Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years

Date: 20 November 2012, 18:54 PM EST
Source: Novartis

Social Media Tools:


Subscribe via RSS

RSSAll Content
RSSConsumer
RSSEntertainment
RSSFinancial
RSSGovernment
RSSHealthcare
RSSRetail
RSSTechnology

Register

Journalists who register may create email subscriptions to search results and a cart of assets to download. Click here to login, register or edit profile.

What Our Users
Are Saying

"I like the way the DC is easy to navigate, easy to find stories, easy to find when they were filed so you know if they’re out of date, and easy to see an on-line version of the available video" -- Allan C Lee, Director of News and Current Affairs